{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=19",
    "query": {
      "intervention": "Placebo, Cohort 3",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:41:15.048Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07158437",
      "title": "Phase 1 Study of SL-325 in Healthy Volunteers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "SL-325",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Normal Saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Shattuck Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2025-09-18",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07158437"
    },
    {
      "nct_id": "NCT04167553",
      "title": "Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obese With Comorbidities",
        "Overweight With Comorbidities",
        "Type2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM15136",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2019-08-30",
      "completion_date": "2020-12-09",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167553"
    },
    {
      "nct_id": "NCT03984812",
      "title": "Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3732394",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-06-17",
      "completion_date": "2020-03-23",
      "has_results": true,
      "last_update_posted_date": "2021-10-25",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984812"
    },
    {
      "nct_id": "NCT04090411",
      "title": "A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Induction- PF-06480605 50 mg SC Q4W",
          "type": "DRUG"
        },
        {
          "name": "Induction- PF-06480605 150 mg SC Q4W",
          "type": "DRUG"
        },
        {
          "name": "Induction- PF-06480605 450 mg SC Q4W",
          "type": "DRUG"
        },
        {
          "name": "Induction- Placebo SC Q4W",
          "type": "OTHER"
        },
        {
          "name": "Chronic- PF-06480605 50 mg SC Q4W",
          "type": "DRUG"
        },
        {
          "name": "Chronic- PF-06480605 150 mg SC Q4W",
          "type": "DRUG"
        },
        {
          "name": "Chronic- PF-06480605 450 mg SC Q4W",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 246,
      "start_date": "2019-12-19",
      "completion_date": "2022-10-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 55,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04090411"
    },
    {
      "nct_id": "NCT03451422",
      "title": "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Efavaleukin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2018-04-10",
      "completion_date": "2021-10-12",
      "has_results": true,
      "last_update_posted_date": "2023-07-19",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03451422"
    },
    {
      "nct_id": "NCT01872572",
      "title": "Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Subcutaneous RB006 0.5 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous RB006 1.0 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous RB006 3.0 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous RB006 2.0 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regado Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2009-08",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-07",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01872572"
    },
    {
      "nct_id": "NCT04426695",
      "title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "REGN10933+REGN10987 combination therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2252,
      "start_date": "2020-06-10",
      "completion_date": "2021-10-22",
      "has_results": true,
      "last_update_posted_date": "2023-01-27",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04426695"
    },
    {
      "nct_id": "NCT06003777",
      "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "PF-06954522",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-08-30",
      "completion_date": "2024-02-20",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06003777"
    },
    {
      "nct_id": "NCT00121641",
      "title": "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1035,
      "start_date": "2005-07",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 83,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 80 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Calera",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121641"
    },
    {
      "nct_id": "NCT01670279",
      "title": "Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "70 Years to 85 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-07",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2016-02-04",
      "last_synced_at": "2026-10-15T17:41:15.048Z",
      "location_count": 4,
      "location_summary": "Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670279"
    }
  ]
}